<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112214</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS13716</org_study_id>
    <secondary_id>1311240</secondary_id>
    <nct_id>NCT02112214</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population</brief_title>
  <acronym>HELPER</acronym>
  <official_title>Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Agency for Research on Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Kandong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital/The Catholic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to define the role of H. pylori eradication in the prevention of
      gastric cancer and its precursors in the context of a population-based endoscopic screening
      program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the decreasing incidence observed in the US and West European countries, gastric
      cancer is still an important global public health problem, especially in East Asian
      countries, where the burden of the disease is substantial. In the Republic of Korea, gastric
      cancer remains the leading cause of cancer in men and the fourth most common cancer in women.
      There is sufficient epidemiological and experimental evidence supporting a causal link
      between bacterial infection with H. pylori and gastric cancer development. However, evidence
      from clinical trials on the efficacy of H. pylori eradication with antimicrobial therapy to
      reduce the risk of gastric cancer is still limited. In addition, the beneficial or
      deleterious health impact of mass eradication at the population level has not been defined.
      In Korea, the prevalence of H. pylori infection in adults is still relatively high (~60%, &gt;16
      years old), and despite important reductions in mortality attributed to the screening
      program, incidence of gastric cancer remains elevated.

      The investigators propose to conduct a randomized controlled clinical trial in Korea to
      evaluate the efficacy of H. pylori eradication to prevent gastric cancer incidence in
      different population subgroups including age and baseline gastric pathology. This study will
      be conducted in the context of the National Cancer Screening Program and the Korean Central
      Cancer Registry.

      The proposed study will be a collaborative investigation between the National Cancer Center,
      Korea and the International Agency for Research on Cancer of the World Health Organization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of gastric cancer between the intervention and placebo groups</measure>
    <time_frame>Up to 10 years After H. pylori eradication</time_frame>
    <description>Histologically confirmed gastric adenocarcinoma stage 1A or more advanced defined at endoscopy or through cancer registry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of gastric dysplasia</measure>
    <time_frame>Up to 10 years After H. pylori eradication</time_frame>
    <description>Diagnosis of histologically confirmed gastric dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events caused by antibiotic treatment</measure>
    <time_frame>During 10 days of H. pylori eradication, and Up To 1 month after the treatment completion</time_frame>
    <description>Solicited/unsolicited adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and mortality from other medical conditions such as obesity, diabetes, circulatory diseases, oesophageal diseases as well as other cancers and cognitive impairment</measure>
    <time_frame>Up to 10 years After H. pylori eradication</time_frame>
    <description>Assessed through record linkage or direct assessment during screening visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality from gastric cancer</measure>
    <time_frame>Up to 10 years after eradication</time_frame>
    <description>Cancer registry or other reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 10 years After H. pylori eradication</time_frame>
    <description>Korean National Health Insurance records or other reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of atrophy score</measure>
    <time_frame>Up to 10 years After H. pylori eradication</time_frame>
    <description>Change in histologic atrophy grade from enrollment to subsequent endoscopic assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">11000</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10-day bismuth-based quadruple therapy for H. pylori positive subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for H. pylori positive subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-day bismuth-based quadruple therapy</intervention_name>
    <description>Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Bismuth-based quadruple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for bismuth-based quadruple therapy</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 40-60 who are invited to participate in the National Cancer
             Screening Program and receive upper endoscopy

          -  Willingness to sign an informed consent form

          -  Good health, as determined by medical history and physical examination at enrollment

        Exclusion Criteria:

          -  Personal history of gastric cancer

          -  Family history of gastric cancer in a first degree relative

          -  Diagnosis and active treatment for other organ cancer except carcinoma in situ within
             5 years

          -  Current treatment for serious medical condition which could hinder participation (such
             as liver cirrhosis, renal failure, pulmonary dysfunction including COPD or asthma, or
             uncontrolled infection)

          -  Inadequate cardiovascular function including (a) New York Heart Association class III
             or IV heart disease, (b) unstable angina or myocardial infarction history, (c) history
             of significant ventricular arrhythmia requiring medication with antiarrhythmics, and
             (d) history of cerebrovascular accident

          -  Requirement for therapeutic anticoagulant therapy, aspirin

          -  Gastric resections due to benign disease

          -  H. pylori eradication therapy history

          -  Mental incompetence to understand and sign informed consent

          -  Alcoholism, drug abuse

          -  Serious chronic diseases according to the evaluation of the study physician

          -  Presence of a contraindication to the use of eradication treatment regimens

          -  Inability to provide an informed consent

          -  Pregnant or lactating women

          -  Treatment required due to peptic ulcer, gastric cancer or esophageal cancer identified
             during the endoscopic examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolando Herrero, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Agency for Research on Cancer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Woo Jeon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwang Ha Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyun Soo Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Gyu Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Soo Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uijongbu St. Mary's Hospital/The Catholic University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Young Park, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Agency for Research on Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <phone>+82-31-920-2282</phone>
    <email>cij1224@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rolando Herrero, M.D., Ph.D.</last_name>
    <phone>+33 4 72 73 86 83</phone>
    <email>HerreroR@iarc.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>620-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>702-911</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
      <phone>+82-31-920-2282</phone>
      <email>cij1224@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-861</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uijongbu St. Mary's Hospital/The Catholic University</name>
      <address>
        <city>Uijongbu</city>
        <zip>480-821</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Il Ju Choi</investigator_full_name>
    <investigator_title>Head of Gastric Cancer Cencer</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori treatment</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

